Acorda Resubmits NDA For Parkinson's Disease Candidate Inbrija
Zacks Investment Research | Dec 08, 2017 03:41AM ET
Acorda Therapeutics (NASDAQ:ACOR) announced that it has resubmitted the new drug application (NDA) for its late stage pipeline candidate, Inbrija, to the FDA. Following the news, shares of the company gained by about 1.9%. So far this year, shares of the company have increased 10.4% compared with the industry ’s gain of 0.7%.
Currently, the company is seeking approval for Inbrija in the United States as a treatment option for symptoms of OFF periods in people with Parkinson’s taking a carbidopa / levodopa regimen.
We remind investors that in August the company received a refusal to file (RTF) letter from the FDA in connection with the new drug application (NDA) that it first submitted in June. However, the FDA declared the application to be incomplete after a preliminary review. As a result, the regulatory body required additional supporting information to review the application.
Notably, the FDA stated two main reasons for the RTF — date specification as to when the manufacturing site can be ready for inspection and questions related to drug master production record. Additionally, the FDA asked for some extra data, unrelated to the main issues of the RTF. Acorda claims that it has addressed these two issues in its resubmission.
Acorda had submitted the NDA as a 505(b)(2) application. The FDA is expected to inform the company within 74 days if the submission is complete and requires a full review.
In this context, we remind investors that in November, Acorda decided to immediately discontinue the phase III study on one of its lead Parkinson’s disease candidates, tozadenant. The decision was based on some serious safety issues observed in the study.
Apart from Acorda, many companies are trying to introduce treatments for Parkinson’s disease in the market namely, Prothena Corporation’s (NASDAQ:PRTA) PRX002, AstraZeneca’s (NYSE:AZN) MEDI1341, Prexton Therapeutics’ Foliglurax and Prana Biotechnology’s PBT434.
Also, Adamas Pharmaceuticals’ (NASDAQ:ADMS) Gocovri received an FDA approval in August for treating dyskinesia in patients with Parkinson’s disease.
Zacks Rank
Acorda carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here .
Get The News You Want
Wall Street’s Next Amazon (NASDAQ:AMZN)
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.